Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Companion Diagnostics Benefit from Fewer Regulatory Barriers in Europe

Published: Thursday, June 26, 2014
Last Updated: Thursday, June 26, 2014
Bookmark and Share
Future revisions to in-vitro diagnostics laws will offset the launch of new tests, in a market expected to soar to $1,295.1 million in 2018.

With the growth in personalized medicine, there is an increased interest in developing companion diagnostics (CDx) tests or tests that match the right therapy to the patient. In fact, over the past few years, market participants have been entering pharmaceutical and diagnostic partnerships in a bid to develop and commercialize CDx tests for drugs that already exist in the market.

Currently, the oncology segment is the focus among players in the CDx market but it is envisioned that non-oncology segments - such as central nervous system, infectious disease, and cardiovascular conditions - will receive immense attention in the years to come.

New analysis from Frost & Sullivan, Western European Companion Diagnostics Market, finds that the market earned revenues of $457 million in 2013 and estimates this to reach $1,295.1 million in 2018 at a compound annual growth rate of 23.2 percent.

The study covers the oncology areas such as breast cancer, colorectal cancer, and lung cancer panel segments and non oncology areas such as infectious, CNS and cardio vascular diseases for Western Europe, including the United Kingdom, Germany, Italy, France, Spain, Benelux and Scandinavia.

“Limited regulatory barriers for drug and diagnostic combination products, which the current in-vitro diagnostic directive classifies under the low-risk category, are easing market access,” said Frost & Sullivan Healthcare Senior Industry Analyst Divyaa Ravishankar. “As nearly all diagnostic tests in Europe belong to the low risk category, they are exempt from pre-market evaluation. Consequently, manufacturers tend to self-assess conformity, self-certify CDx products, and CE mark them before sale in the European market. This laid-back process has resulted in a higher rate of approval of new CDx tests and products.”

However, intense competition from laboratory-developed test (LDT) manufacturers - who offer tests through reference laboratories across Europe and the rest of the world - is hampering market growth.

The entry of foreign LDT companies into the market through partnership with local companies, as well as the inclination of companies across Western Europe to promote the use of LDT over manufactured and approved CDx tests, is exacerbating the situation.

Further, the variation in reimbursement policies across Western Europe is creating an unpredictable environment, adversely affecting the uptake of new CDx test technologies. Along with the lack of a robust coverage and payment process, this is denting the prospects of CDx manufacturers in the region.

“CDx manufacturers should partner with regulatory bodies from the early stages of solution development to gain an advantage over drug companies,” advised Ravishankar. “Diagnostics companies should also devise effective business models that rest on shortening the drug development time and earning royalties for future sales.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Increased Public Private Partnerships to Drive Cutting Edge Innovation and Business Growth
Faced with increasing challenges such as costly treatments and treatments that are palliative rather than symptomatic, the global healthcare industry today is gradually transforming itself.
Thursday, October 08, 2015
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Monday, August 24, 2015
Changing Phase of Biomarkers
Discover the current scenario and changing business models of the biomarkers field.
Monday, April 13, 2015
Can Regenerative Medicine be the Cure for Cancer and Other Deadly Diseases?
Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products.
Thursday, June 19, 2014
Gene Expression Profiling Drives Personalized Medicine Worldwide
Large amounts of information generated by gene expression profiling will increase implementation of data management tools.
Tuesday, June 10, 2014
Personalized Medicine Drives Uptake of Next-generation Sequencing in Europe
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years.
Saturday, May 31, 2014
Emerging Technologies Redefine Infectious Disease Diagnostics
The largest opportunities lie in the developing regions of Asia, Africa and Latin America.
Wednesday, April 23, 2014
Drug Developers Drawn to Orphan Drugs Market
Breakthrough therapies for rare diseases command premium pricing, particularly if no alternatives exist.
Thursday, March 27, 2014
Next-Generation Therapeutics for Infectious Diseases Conquer the Global Spotlight
Resistance to current drugs spurs treatment innovation in influenza, respiratory syncytial virus, chlamydia and gonorrhea.
Thursday, March 27, 2014
Live Cell Imaging Revolutionizes Disease Diagnostics and Drug Discovery
Stakeholder collaboration will be crucial to convert these developments into clinically meaningful tests.
Friday, March 21, 2014
Automated Anatomic Pathology Labs Transform Global Tissue Diagnostics Market
Offering attractive procurement strategies will boost adoption of high-end tools.
Thursday, February 06, 2014
Strong Pipeline of mAbs Biosimilars in the US and Europe Lends Impetus to Global Market
The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019.
Tuesday, February 04, 2014
Predictions for the Global Chemicals, Materials and Food Industry
New insights based on Frost & Sullivan's ‘2013 Search for Growth’ survey.
Wednesday, December 11, 2013
CMOs Can Reduce Vendor Switching with Informational Marketing Efforts
Frost & Sullivan: Companies opt for CMOs offering high-quality services, confidentiality and clean regulatory track records.
Tuesday, November 26, 2013
Next Generation Sequencing Bioinformatics Heats up: Nearing $1000 Genome Sparks Soaring Data Output
Frost & Sullivan: Healthcare innovation hinges on managing escalating amounts of data priming to more than triple the market.
Wednesday, November 13, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos